非缺血性心肌病患者伴或不伴左室壁中层纤维化时心脏再同步治疗除颤与起搏的结局比较
本研究在68例伴左室壁中层纤维化(+MWF)和184例不伴MWF(-MWF)的非缺血性心肌病(NICM)患者中,比较心脏再同步治疗除颤(CRT-D)与起搏(CRT-P)的临床结局。结果发现+MWF是死亡和心衰住院的独立预测因子,且仅在+MWF患者中CRT-D较CRT-P降低总死亡率、总死亡或心衰住院、总死亡或主要不良心脏事件住院。
要点
- +MWF是NICM患者死亡和心衰住院的独立预测因子。
- 仅在+MWF患者中,CRT-D较CRT-P降低总死亡率及复合终点。
- 在-MWF患者中,未观察到CRT-D优于CRT-P。
核心结论
- 在NICM患者中,CRT-D仅在伴左室壁中层纤维化(+MWF)时优于CRT-P,在不伴MWF(-MWF)时未显示优势。
研究设计与样本
- 回顾性队列研究,纳入68例+MWF和184例-MWF的NICM患者,均在CRT装置植入前接受心脏磁共振检查。
- 随访最长14年,+MWF中位随访3.8年(IQR 2.0-6.1),-MWF中位随访4.6年(IQR 2.4-8.3)。
主要发现
- +MWF是全因死亡的独立预测因子(aHR 2.31,95%CI 1.45-3.68)。
- +MWF是全因死亡或心衰住院的独立预测因子(aHR 2.02,95%CI 1.32-3.09)。
- +MWF是全因死亡或主要不良心脏事件住院的独立预测因子(aHR 2.02,95%CI 1.32-3.07)。
- +MWF是泵衰竭死亡(aHR 1.95,95%CI 1.11-3.41)和心源性猝死(aHR 3.75,95%CI 1.26-11.2)的独立预测因子。
- 在+MWF患者中,CRT-D较CRT-P降低全因死亡(aHR 0.23,95%CI 0.07-0.75)、全因死亡或心衰住院(aHR 0.32,95%CI 0.12-0.82)、全因死亡或主要不良心脏事件住院(aHR 0.30,95%CI 0.12-0.78);在-MWF患者中无此差异。
临床怎么用
- 对于NICM患者,可考虑通过心脏磁共振检测左室壁中层纤维化以辅助选择CRT-D或CRT-P。
- 伴MWF的NICM患者可能从CRT-D而非CRT-P中获得生存获益。
- 不伴MWF的NICM患者中,CRT-D未显示优于CRT-P,器械选择需个体化。
局限性
- 研究为单中心回顾性设计,样本量有限(+MWF 68例,-MWF 184例)。
- 原文未报告CRT-P与CRT-D组间的基线特征比较及混杂因素调整细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent studies have cast doubt on the benefit of cardiac resynchronization therapy (CRT) with defibrillation (CRT-D) versus pacing (CRT-P) for patients with nonischemic cardiomyopathy (NICM). Left ventricular myocardial scar portends poor clinical outcomes. OBJECTIVES: The aim of this study was to determine whether CRT-D is superior to CRT-P in patients with NICM either with (+) or without (-) left ventricular midwall fibrosis (MWF), detected by cardiac magnetic resonance. METHODS: Clinical events were quantified in patients with NICM who were +MWF (n = 68) or -MWF (n = 184) who underwent cardiac magnetic resonance prior to CRT device implantation. RESULTS: In the total study population, +MWF emerged as an independent predictor of total mortality (adjusted hazard ratio [aHR]: 2.31; 95% confidence interval [CI]: 1.45 to 3.68), total mortality or heart failure hospitalization (aHR: 2.02; 95% CI: 1.32 to 3.09), total mortality or hospitalization for major adverse cardiac events (aHR: 2.02; 95% CI: 1.32 to 3.07), death from pump failure (aHR: 1.95; 95% CI: 1.11 to 3.41), and sudden cardiac death (aHR: 3.75; 95% CI: 1.26 to 11.2) over a maximum follow-up period of 14 years (median 3.8 years [interquartile range: 2.0 to 6.1 years] for +MWF and 4.6 years [interquartile range: 2.4 to 8.3 years] for -MWF). In separate analyses of +MWF and -MWF, total mortality (aHR: 0.23; 95% CI: 0.07 to 0.75), total mortality or heart failure hospitalization (aHR: 0.32; 95% CI: 0.12 to 0.82), and total mortality or hospitalization for major adverse cardiac events (aHR: 0.30; 95% CI: 0.12 to 0.78) were lower after CRT-D than after CRT-P in +MWF but not in -MWF. CONCLUSIONS: In patients with NICM, CRT-D was superior to CRT-P in +MWF but not -MWF. These findings have implications for the choice of device therapy in patients with NICM.
引用
- Leyva F, Zegard A, Acquaye E, et al. Outcomes of Cardiac Resynchronization Therapy With or Without Defibrillation in Patients With Nonischemic Cardiomyopathy. J Am Coll Cardiol. 2017. PMID: 28859784. doi:10.1016/j.jacc.2017.07.712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。